Skip to main content
    E

    Editas Medicine Inc (EDIT)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.87
    -0.30 (-13.82%)

    Market Cap: $334.92M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Editas Medicine Inc (EDIT) Financials: Revenue, Profit and Cash Flow

    Updated Nov 9, 2026. Financial statements from company filings, amounts in US dollars.

    Editas Medicine reported revenue of $40.52M for the fiscal year ended Dec 31, 2025. That year, net income was -$160.06M with a net margin of -395.0%, operating cash flow was -$165.24M and free cash flow was -$165.85M. The quarter ended Sep 30, 2026 had revenue of $10.37M and net income of -$23.39M.

    Revenue and Margins

    Over the 9 years to Dec 2025, revenue grew from $6.05M, a compound annual rate of 23.5%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$40.52MN/A100.0%-394.9%-395.0%
    Dec 2024$0-100.0%N/AN/AN/A
    Dec 2023$78.12M+296.3%100.0%-216.6%-196.1%
    Dec 2022$19.71MN/A100.0%-1146.3%-1118.3%
    Dec 2021$0-100.0%N/AN/AN/A
    Dec 2020$90.73M+341.9%100.0%-148.6%-127.8%
    Dec 2019$20.53MN/A100.0%-686.4%-651.4%
    Dec 2018$0-100.0%N/AN/AN/A
    Dec 2017$13.73M+126.8%100.0%-873.6%-876.5%
    Dec 2016$6.05MN/A100.0%-1605.6%-1605.5%
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss narrowed from the year before. In the quarter ended Sep 2026, the net loss narrowed from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$40.52M$0$78.12M$19.71M$0$90.73M$20.53M$0$13.73M$6.05M
    Gross profit$40.52M$0$78.12M$19.71M$0$90.73M$20.53M$0$13.73M$6.05M
    Research and development$89.95M$166.93M$177.65M$174.96M$116.96M$158.00M$96.90M$58.72M$83.16M$56.98M
    Operating income-$160.01M-$251.15M-$169.18M-$225.95M-$193.15M-$134.84M-$140.92M-$113.73M-$119.93M-$97.19M
    Net income-$160.06M-$237.09M-$153.22M-$220.43M-$192.50M-$115.98M-$133.75M-$109.95M-$120.32M-$97.18M
    EBITDA-$156.92M-$245.35MN/A-$220.34M-$186.40M-$114.62M-$138.23M-$110.14M-$116.66M-$96.04M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$10.37M$11.89M$0$29.40M$7.54M$3.58M$0-$1.14M$0$0$1.14M$60.05M
    Gross profit$10.37M$11.89M$0$29.40M$7.54M$3.58M$0-$1.14M$0$0$1.14M$60.05M
    Operating income-$24.28M-$18.55M-$25.00M-$7.75M-$24.55M-$51.54M-$76.16M-$46.59M-$65.67M-$71.90M-$66.99M-$23.96M
    Net income-$23.39M-$18.23M-$24.98M-$5.62M-$25.12M-$53.23M-$76.09M-$45.40M-$62.14M-$67.61M-$61.95M-$18.87M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded total debt of $58.60M by $88.04M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$186.53M$341.59M$499.15M$514.32M$677.48M$572.60M$508.88M$420.39M$373.26M$229.18M
    Current assets$163.90M$289.31M$340.83M$356.75M$507.31M$419.09M$463.84M$374.78M$332.20M$187.18M
    Cash and equivalents$146.65M$131.54M$123.65M$141.52M$203.52M$139.68M$238.18M$134.78M$146.63M$185.32M
    Total liabilities$159.25M$207.31M$150.06M$153.64M$123.84M$179.02M$246.45M$184.22M$165.18M$94.58M
    Short-term debt$5.00M$5.00M$0$11.08M$10.31M$6.81M$5.80M$12.81M$7.50M$10.00M
    Long-term debt$53.60M$52.43M$0N/AN/AN/AN/AN/A$33.43M$35.10M
    Shareholder equity$27.29M$134.27M$349.10M$360.68M$553.64M$393.59M$262.44M$236.16M$208.08M$134.61M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$219.41M$237.36M$149.34M$186.53M$201.75M$210.58M$263.65M$341.59M$327.57M$384.80M$440.35M$499.15M
    Total liabilities$134.89M$132.08M$144.93M$159.25M$188.30M$191.39M$201.23M$207.31M$151.93M$152.79M$145.95M$150.06M
    Cash and equivalents$93.17M$181.81M$123.65M$146.65M$165.65M$138.54M$138.69M$131.54M$95.83M$64.44M$69.23M$123.65M
    Shareholder equity$84.52M$105.28M$4.41M$27.29M$13.45M$19.19M$62.42M$134.27M$175.63M$232.01M$294.40M$349.10M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow-$165.24M-$210.28M-$132.18M-$177.35M-$163.80M-$179.84M-$40.67M-$45.71M-$9.42M-$50.25M
    Capital expenditures$607.00K$8.83M$4.72M$4.12M$7.98M$7.16M$6.17M$4.75M$2.06M$3.49M
    Free cash flow-$165.85M-$219.11M-$136.90M-$181.47M-$171.78M-$187.00M-$46.84M-$50.46M-$11.48M-$53.74M
    Dividends paidN/AN/AN/AN/AN/AN/AN/A$4.00K$11.00K$782.00K
    Investing cash flow$138.67M$162.15M-$3.73M$114.07M-$54.47M-$140.52M$12.25M-$53.09M-$183.81M-$3.47M
    Financing cash flow$40.47M$56.03M$118.04M$1.28M$282.11M$224.12M$131.82M$86.94M$154.53M$97.16M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$21.19M-$29.57M-$23.06M-$36.39M-$30.84M-$50.21M-$47.80M-$50.76M-$52.59M-$57.06M-$49.87M-$22.24M
    Capital expendituresN/A$106.00K$92.00K$60.00K$433.00K$0$114.00K$540.00K$2.92M$3.49M$1.87M$1.31M
    Free cash flowN/A-$29.67M-$23.15M-$36.45M-$31.28M-$50.21M-$47.91M-$51.30M-$55.51M-$60.56M-$51.74M-$23.55M
    Last 12 quarters

    Frequently Asked Questions About EDIT

    What is Editas Medicine's annual revenue?

    Editas Medicine reported revenue of $40.52M for the fiscal year ended Dec 31, 2025.

    Is Editas Medicine profitable?

    No. Editas Medicine reported net income of -$160.06M for the fiscal year ended Dec 31, 2025, with a net margin of -395.0%.

    How much free cash flow does EDIT generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$165.24M minus capital expenditures of $607.00K produced free cash flow of -$165.85M.

    How much debt does Editas Medicine have?

    The balance sheet dated Dec 31, 2025 reported long-term debt of $53.60M, short-term debt of $5.00M and cash and equivalents of $146.65M.

    What is EDIT's profit margin?

    For the fiscal year ended Dec 31, 2025, Editas Medicine reported gross margin of 100.0%, operating margin of -394.9% and net margin of -395.0%.